Pharmacology

Niiki Pharma Announces The Completion Of Phase I Dose Escalation For First-in-Man Anti-Cancer Agent NKP-1339

HOBOKEN, New Jersey and PHILADELPHIA, January 17, 2012 /PRNewswire/--- Trial Demonstrates Favorable Safety Profile with Anti-Tumor Activity Niiki Pharma Inc. announced today that it has completed the dose escalation portion of the Phase I clinical trial o ...

Article - Anna Ohlden - Jan 17 2012 - 1:30pm

Memory: Even Decaffeinated Coffee Is Awesome

It may turn out that coffee is bad for you. The World Health Organization already lists it as a possible carcinogen, despite any evidence, but they do the same thing about cell phones, in contrast to any evidence- perhaps Big Tea donates a lot to WHO. Unti ...

Article - News Staff - Feb 1 2012 - 2:01pm

Genetic Modification Plus Big Pharm Equals Anti-Science Hippie Meltdown

What's the one thing that could make anti-science progressives dislike genetic modifications and medicine even more than they do now?  Putting them both together. ...

Article - Hank Campbell - Feb 24 2012 - 1:04am

Berries Benefit Brains?

Evidence suggests that eating blueberries, blackberries, strawberries and other berry fruits has beneficial effects on the brain and may help prevent age-related memory loss and other changes, scientists report.  In a new review, Barbara Shukitt-Hale, Ph. ...

Article - News Staff - Mar 8 2012 - 8:00am

Results From Study Of Eisai's Investigational Epilepsy Treatment Perampanel

Eisai today announces the publication of results from a pivotal Phase III study of perampanel, an investigational, highly selective, non-competitive AMPA-type glutamate receptor antagonist developed as an adjunctive therapy for partial seizures in adult p ...

Article - Anna Ohlden - Apr 18 2012 - 5:46pm

Positive SNG001 Phase II Asthma Clinical Trial Data

Synairgen plc, announces positive data from its Phase II clinical trial. This pioneering trial investigated the potential for SNG001 (inhaled interferon beta) to protect asthmatics from respiratory virus infections (principally the common cold) that can s ...

Article - Anna Ohlden - Apr 20 2012 - 5:30am

New Data Suggests Interferon-Free Therapy Around The Corner For HCV Patients

 Further data shows PegIFN-lambda's comparable efficacy but better safety profile than PegIFN-alpha   New data presented at the International Liver Congress(TM) 2012 shows consolidation of the interferon-free (IFN) revolution in HCV treatment. The mu ...

Article - Anna Ohlden - Apr 21 2012 - 2:30am

Final Phase 2a Study Results For Miravirsen Showing Dose-dependent, Prolonged Antiviral Activity In Hepatitis C Patients

Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, will present final data from a Phase 2a trial showing that miravirsen given as a four-week monotherapy treatment provided r ...

Article - Anna Ohlden - Apr 19 2012 - 5:30pm

Positive Results From Interferon-Free Phase 2 "Co-Pilot" Study For The Treatment Of Hepatitis C

Abbott and Enanta Pharmaceuticals announced data from "Co-Pilot," an interferon-free, Phase 2 study of Abbott's direct-acting antiviral medicines for the treatment of hepatitis C (HCV) that found that more than 90 percent of patients new to ...

Article - Anna Ohlden - Apr 19 2012 - 4:30pm

Positive Results From Phase 2 "Pilot" Study Of An Interferon-Free Combination Regimen For The Treatment Of Hepatitis C

  Abbott and Enanta Pharmaceuticals announced complete data from the study known as "Pilot"- Abbott's initial interferon-free study of its direct-acting antiviral agents for the treatment of hepatitis C (HCV)- showing that 91 percent of gen ...

Article - Anna Ohlden - Apr 19 2012 - 11:56am